Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
Tango Therapeutics Inc (NASDAQ: TNGX) closed the day trading at $9.17 down -3.68% from the previous closing price of $9.52. In other words, the price has decreased by -$3.68 from its previous closing price. On the day, 2.0 million shares were traded. TNGX stock price reached its highest trading level at $9.7 during the session, while it also had its lowest trading level at $9.095.
Ratios:
For a better understanding of TNGX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.75 and its Current Ratio is at 4.75. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Piper Sandler on August 19, 2025, initiated with a Overweight rating and assigned the stock a target price of $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 25 ’25 when Third Rock Ventures IV, L.P. sold 500,000 shares for $8.02 per share. The transaction valued at 4,008,500 led to the insider holds 13,863,975 shares of the business.
Third Rock Ventures IV, L.P. bought 500,000 shares of TNGX for $3,900,000 on Sep 25 ’25. On Sep 16 ’25, another insider, Third Rock Ventures IV, L.P., who serves as the 10% Owner of the company, sold 363,541 shares for $7.04 each. As a result, the insider received 2,559,329 and left with 14,363,975 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNGX now has a Market Capitalization of 1020256512 and an Enterprise Value of 874479488. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.99 while its Price-to-Book (P/B) ratio in mrq is 7.53. Its current Enterprise Value per Revenue stands at 35.993 whereas that against EBITDA is -5.649.
Stock Price History:
The Beta on a monthly basis for TNGX is 1.66, which has changed by 0.22922254 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, TNGX has reached a high of $9.55, while it has fallen to a 52-week low of $1.03. The 50-Day Moving Average of the stock is 25.69%, while the 200-Day Moving Average is calculated to be 119.52%.
Shares Statistics:
Over the past 3-months, TNGX traded about 2.05M shares per day on average, while over the past 10 days, TNGX traded about 2155990 shares per day. A total of 110.87M shares are outstanding, with a floating share count of 64.33M. Insiders hold about 42.18% of the company’s shares, while institutions hold 73.25% stake in the company. Shares short for TNGX as of 1759190400 were 33812698 with a Short Ratio of 16.52, compared to 1756425600 on 25400631. Therefore, it implies a Short% of Shares Outstanding of 33812698 and a Short% of Float of 36.46.
Earnings Estimates
A detailed examination of Tango Therapeutics Inc (TNGX) is currently in progress, with 8.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.34, with high estimates of -$0.25 and low estimates of -$0.39.
Analysts are recommending an EPS of between -$0.95 and -$1.49 for the fiscal current year, implying an average EPS of -$1.09. EPS for the following year is -$1.42, with 7.0 analysts recommending between -$1.1 and -$1.83.
Revenue Estimates
8 analysts predict $41.34M in revenue for. The current quarter. It ranges from a high estimate of $53.81M to a low estimate of $3.18M. As of. The current estimate, Tango Therapeutics Inc’s year-ago sales were $11.61M
A total of 8 analysts have provided revenue estimates for TNGX’s current fiscal year. The highest revenue estimate was $62.4M, while the lowest revenue estimate was $14.94M, resulting in an average revenue estimate of $53.92M. In the same quarter a year ago, actual revenue was $42.07M
